PARP11 Homogenous Assay Kit
The PARP11 Homogeneous Assay Kit is designed to measure PARP11 (poly-(ADP-ribose) polymerase 11) activity for screening and profiling applications. The PARP11 Homogeneous Assay Kit comes in a convenient 384-well AlphaLISA® format, with enough purified recombinant PARP11 (amino acids 8-338), biotinylated histone substrate, ADP-Ribose Binding Reagent 1 and assay buffer for 400 enzyme reactions.
Figure 1: PARP11 Homogenous Assay Kit schematic.
A sample containing PARP11 is incubated with a biotinylated histone substrate and NAD+ for one hour. This is followed by the addition of acceptor beads and ADP-Ribose Binding Reagent 1, and finally donor beads. Alpha-counts are then measured. Alpha-counts are directly proportional to PARP11 activity.
Need us to run inhibitor screens or profile your compounds against PARP11? Check out our PARP/PARPTrap™ Screening Services or DNA Replication and Repair Screening Services.
- AlphaLISA® Anti-Rabbit IgG Acceptor Beads (Perkin Elmer #AL104C)
- AlphaScreen® Streptavidin-Conjugated Donor Beads (Perkin Elmer #6760002S)
- Optiplate - 384 (Perkin Elmer #6007290)
- AlphaScreen microplate reader
| Catalog # | Name | Amount | Storage |
| 80511 | PARP11, GST-Tag, His-Tag* | 40 µg | -80°C |
| 5X PP-01 Assay Buffer | 2 x 1 ml | -80°C | |
| Biotinylated Histone Substrate | 500 reactions | -80°C | |
| 78311 | ADP-Ribose Binding Reagent 1 | 10 µl | -80°C |
| 750 µM NAD+ | 400 µl | -80°C | |
| 0.5 mM DTT | 200 µl | -20°C | |
| 4X Detection buffer 1NP | 2 ml | -20°C |
*The initial concentration of enzyme is lot-specific and will be indicated on the tube containing the protein
PARP11, also known as poly-(ADP-ribose) polymerase 11 or NAD+ ADP-ribosyltransferase 11, is part of the PARP family. ADP ribosylation, which is the addition of an ADP-ribose to a protein, is a reversible post-translational modification of proteins mostly involved in the DNA Damage Response (DDR) pathway. Mono-ADP-ribosylation (termed MARylation) is the addition of a unit of ADP-ribose. PARP11 is involved in MARylation of β-TrCP (β-transducin repeat containing protein), an E3 ligase that ubiquitinates and targets IFNAR1 (IFNα/β receptor subunit 1) for degradation, restricting the potency of IFN-I (interferon type I) response to viral infections. PARP11 contributes to an immunosuppressive TME (tumor microenvironment) by downregulating IFNAR1 and decreasing the potency of CD8+ T cells to kill cancer cells. The use of inhibitors to PARP11 or engineered T cells to decrease PARP11 activity can prove beneficial in cancer therapy.
Zhang H., et al., 2022 Nat Cancer 3(7): 808-820.
Guo T., et al., 2019 Nat Microbiol 4(11):1872-1884.
Powered by Bioz
San Diego, CA 92121
858-202-1401
Products are for Research Use Only
COMPANY
Copyright © 2024
BPS Bioscience, Inc.
All rights reserved.
Diagrams on this website are created with BioRender.com.